IN2014CN04742A - - Google Patents

Info

Publication number
IN2014CN04742A
IN2014CN04742A IN4742CHN2014A IN2014CN04742A IN 2014CN04742 A IN2014CN04742 A IN 2014CN04742A IN 4742CHN2014 A IN4742CHN2014 A IN 4742CHN2014A IN 2014CN04742 A IN2014CN04742 A IN 2014CN04742A
Authority
IN
India
Prior art keywords
domain
polypeptides
influenza hemagglutinin
influenza
stem segment
Prior art date
Application number
Other languages
English (en)
Inventor
Jan Wilem Meijberg
Antonietta Impagliazzo
Ronald Vogels
Robert Heinz Edward Friesen
Philippe Alard
Stefan Loverix
Katarina Radoševic
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of IN2014CN04742A publication Critical patent/IN2014CN04742A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN4742CHN2014 2011-11-28 2012-11-27 IN2014CN04742A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564198P 2011-11-28 2011-11-28
US201161564086P 2011-11-28 2011-11-28
EP11191009 2011-11-28
EP11191003 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (fr) 2011-11-28 2012-11-27 Vaccins contre le virus de la grippe et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2014CN04742A true IN2014CN04742A (fr) 2015-09-18

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4742CHN2014 IN2014CN04742A (fr) 2011-11-28 2012-11-27

Country Status (20)

Country Link
US (3) US9452211B2 (fr)
EP (2) EP2785372B1 (fr)
JP (1) JP6294828B2 (fr)
KR (1) KR101983989B1 (fr)
CN (1) CN104066446B (fr)
AR (1) AR089005A1 (fr)
AU (1) AU2012343981B2 (fr)
BR (1) BR112014012681A8 (fr)
CA (1) CA2857087C (fr)
EA (1) EA033386B1 (fr)
HK (1) HK1199211A1 (fr)
IL (1) IL232780A (fr)
IN (1) IN2014CN04742A (fr)
MX (1) MX357009B (fr)
MY (1) MY170927A (fr)
PH (1) PH12014501118A1 (fr)
SG (1) SG11201402633UA (fr)
TW (1) TWI618715B (fr)
WO (1) WO2013079473A1 (fr)
ZA (1) ZA201404797B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413962A1 (fr) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Vaccins pour le virus influenza et leurs utilisations
EP2536425B1 (fr) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
EP2758075B1 (fr) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
MX357009B (es) 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
JP2015519348A (ja) * 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (fr) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Anticorps contre l'hémagglutinine du virus de la grippe et utilisations correspondantes
CN105452270B (zh) * 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
EP3805254A1 (fr) * 2013-08-03 2021-04-14 Calder Biosciences Inc. Méthodes de préparation et d'utilisation de complexes d'hemagglutinine du virus influenza
US10344058B2 (en) 2014-05-01 2019-07-09 Indian Institute Of Science Polypeptides for generating anti-influenza antibodies and uses thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10400034B2 (en) 2014-06-26 2019-09-03 Janssen Vaccines & Prevention, B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
SG11201610443WA (en) * 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
WO2016005482A1 (fr) * 2014-07-10 2016-01-14 Crucell Holland B.V. Vaccins contre le virus influenza et leurs utilisations
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016261299B2 (en) * 2015-05-11 2019-12-05 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
US10538557B2 (en) 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
WO2017218624A1 (fr) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Hémagglutinines du virus de la grippe et utilisations de celles-ci
CN118146389A (zh) * 2016-09-02 2024-06-07 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
WO2018053178A1 (fr) * 2016-09-16 2018-03-22 Vaccitech, Inc. Compositions et méthodes pour la vaccination contre l'influenza
US20190314486A1 (en) * 2016-10-21 2019-10-17 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2019100147A1 (fr) * 2017-11-22 2019-05-31 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Hémagglutinine synthétique en tant que vaccin universel contre une infection par des virus de la grippe de type b (ibv)
AU2018388102A1 (en) * 2017-12-21 2020-07-16 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
MX2021012991A (es) * 2019-04-25 2021-12-10 Janssen Vaccines & Prevention Bv Antigenos de gripe recombinantes.
CN114430742A (zh) * 2019-09-05 2022-05-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
EP4045517A2 (fr) * 2019-10-15 2022-08-24 Janssen Vaccines & Prevention B.V. Vaccins contre le virus de la grippe et leurs utilisations
WO2022051327A1 (fr) * 2020-09-02 2022-03-10 St. Jude Children's Research Hospital, Inc. Modifications d'hémagglutinine pour une production améliorée d'un vaccin contre la grippe
CN116528893A (zh) 2020-09-07 2023-08-01 英特维特国际股份有限公司 用于ha抗体阳性靶标的ha茎疫苗
WO2023274860A1 (fr) * 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Nouveaux antigènes de la grippe
WO2024038382A1 (fr) * 2022-08-16 2024-02-22 Seqirus Inc. Virus de la grippe modifiés
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (fr) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE60116513T2 (de) 2000-08-10 2006-09-21 Crucell Holland B.V. Adenovirenvektoren zur transduktion der chondrozyten
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
ES2310247T3 (es) 2002-04-25 2009-01-01 Crucell Holland B.V. Vectores adenovirales estables y metodos de propagacion de los mismos.
SI1497438T1 (sl) 2002-04-25 2010-03-31 Crucell Holland Bv Sredstva in postopki za pripravo adenovirusnih vektorjev
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1553983A2 (fr) 2002-10-23 2005-07-20 Crucell Holland B.V. Nouveaux parametres pour vaccins a base d'adenoviraux recombinants
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CN1863918B (zh) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
WO2008028946A2 (fr) 2006-09-07 2008-03-13 Crucell Holland B.V. Molécules de liaison humaines capables de neutraliser le virus de la grippe h5n1 et leurs utilisations
EP2413962A1 (fr) * 2009-03-30 2012-02-08 Mount Sinai School of Medicine Vaccins pour le virus influenza et leurs utilisations
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
KR20130075732A (ko) * 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA027054B1 (ru) 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EP2780034A1 (fr) 2011-11-14 2014-09-24 Crucell Holland B.V. Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
MX357009B (es) 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US9512201B2 (en) 2012-09-27 2016-12-06 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
CN105452270B (zh) 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
WO2016005482A1 (fr) 2014-07-10 2016-01-14 Crucell Holland B.V. Vaccins contre le virus influenza et leurs utilisations
SG11201610443WA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
US9452211B2 (en) 2016-09-27
JP2015502353A (ja) 2015-01-22
US20160362455A1 (en) 2016-12-15
US9969778B2 (en) 2018-05-15
MX357009B (es) 2018-06-22
AU2012343981B2 (en) 2017-09-07
EP2785372B1 (fr) 2019-06-19
JP6294828B2 (ja) 2018-03-14
CN104066446A (zh) 2014-09-24
US20140357845A1 (en) 2014-12-04
BR112014012681A2 (pt) 2017-06-13
CN104066446B (zh) 2017-10-03
IL232780A (en) 2017-09-28
KR20140099515A (ko) 2014-08-12
EA033386B1 (ru) 2019-10-31
BR112014012681A8 (pt) 2017-06-20
WO2013079473A1 (fr) 2013-06-06
CA2857087C (fr) 2021-05-25
IL232780A0 (en) 2014-07-31
ZA201404797B (en) 2022-03-30
PH12014501118B1 (en) 2014-08-04
HK1199211A1 (en) 2015-06-26
EA201491051A1 (ru) 2015-04-30
PH12014501118A1 (en) 2014-08-04
AR089005A1 (es) 2014-07-23
TWI618715B (zh) 2018-03-21
MX2014006396A (es) 2014-07-22
SG11201402633UA (en) 2014-09-26
TW201329101A (zh) 2013-07-16
MY170927A (en) 2019-09-19
AU2012343981A1 (en) 2014-07-10
CA2857087A1 (fr) 2013-06-06
EP3566714A1 (fr) 2019-11-13
US20160355553A1 (en) 2016-12-08
EP2785372A1 (fr) 2014-10-08
NZ625973A (en) 2016-09-30
KR101983989B1 (ko) 2019-05-31

Similar Documents

Publication Publication Date Title
IN2014CN04742A (fr)
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
IN2014CN00953A (fr)
EA201171220A1 (ru) Мутанты fgf21 и их применение
EP3936141A3 (fr) Composés anti-sénescence et leurs utilisations
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
WO2015020913A3 (fr) Protéines d'hémagglutinine de la grippe et méthodes associées
MX350445B (es) Analogos del factor b del complemento y sus usos.
NI201700156A (es) Péptidos lipidados resistentes a proteasas
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
SG10201908920QA (en) Influenza virus vaccines and uses thereof
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
WO2015171395A3 (fr) Biocapteurs à base de peptides résistant à la dégradation
WO2010111597A3 (fr) Compositions immunodominantes et leurs procédés d'utilisation
CU20140061A7 (es) Vacunas contra virus influenza y sus usos
BG111616A (bg) Екстракти от охлюв helix aspersa
MY155338A (en) Novel insulin derivatives having an extremely delayed time-action profile